NPPA revises ceiling price of 53 scheduled drugs, Details
New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA), the Ministry of Chemicals and Fertilizers, the Government of India has revised the ceiling price of the 53 scheduled formulations under the Drug (Price Control) Order,2013.The list of 53 scheduled formulations includes Omeprazole, Colchicine, Amoxicillin, Dexamethasone, Prednisolone,...
New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA), the Ministry of Chemicals and Fertilizers, the Government of India has revised the ceiling price of the 53 scheduled formulations under the Drug (Price Control) Order,2013.
The list of 53 scheduled formulations includes Omeprazole, Colchicine, Amoxicillin, Dexamethasone, Prednisolone, Azithromycin, Doxycycline, Paracetamol, Sodium Valproate, Cholecalciferol, Gefitinib, Mycophenolate mofetil, Ceftazidime, Xylometazoline, Bisacodyl, Levetiracetam, Ondansetron, Methylergometrine, Cytosine arabinoside, Ketamine, Vincristine, Tramadol, Oxytocin, Cetirizine, Amoxicillin plus Clavulanic acid, Rituximab, Sodium bicarbonate and others.
This came in line with the decision of the 108th Authority meeting dated 2nd February 2023, where the ceiling price fixation of scheduled formulations under the Drug (Price Control) Order 2013 (National List Of Essential Medicine 2022) was discussed.
Scheduled formulation means any formulation, included in the First Schedule whether referred to by generic versions or brand names (mainly products covered under the National List of Essential Medicines are Scheduled Formulation). In other words, all medicines that are covered in the National List of Essential Medicine, which are notified in Schedule 1, by the Govt. are scheduled formulation.
"Ceiling Price" refers to a price fixed by the Government for Scheduled Formulations in accordance with the provisions of the drugs (prices control) order, 2013. The ceiling Price is the Maximum Price to Retailer (excluding Taxes, if any)for the given product.
The notice declared that in exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No SO 1499(E) dated 30th March, 2022 in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority has fixed the price as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:
Sl. No. | Name of the Scheduled Formulation | Dosage form and strength | Unit | Ceiling Price (Rs.) |
(1) | (2) | (3) | (4) | (5) |
1 | Omeprazole | Capsule 20 mg | 1 Capsule | 2.56 |
2 | Colchicine | Tablet 0.5mg | 1 Tablet | 2.91 |
3 | Amoxicillin | Capsule 500mg | 1 Capsule | 6.56 |
4 | Dexamethasone | Tablet 0.5mg | 1 Tablet | 0.20 |
5 | Prednisolone | Tablet 10mg | 1 Tablet | 1.07 |
6 | Prednisolone | Tablet 5mg | 1 Tablet | 0.61 |
7 | Tablet 250mg | 1 Tablet | 10.39 | |
8 | Azithromycin | Tablet 500mg | 1 Tablet | 21.02 |
9 | Prednisolone | Tablet 20mg | 1 Tablet | 2.14 |
10 | Doxycycline | Capsule 100mg | 1 Capsule | 2.75 |
11 | Paracetamol | Tablet 500mg | 1 Tablet | 0.80 |
12 | Sodium Valproate | Oral liquid 200mg/5mL(p) | 1 ML | 0.58 |
13 | Cholecalciferol | Solid oral dosage form 60000 IU Tablets | 1 Tablet | 20.07 |
Sl. No. | Name of the Scheduled Formulation | Dosage form and strength | Unit | Ceiling Price (Rs.) |
14 | Gefitinib | Tablet 250mg | 1 Tablet | 211.49 |
15 | Mycophenolate mofetil | Tablet 250mg | 1 Tablet | 44.24 |
16 | Ceftazidime | Powder for Injection 250 mg | 1 Vial | 70.52 |
17 | Xylometazoline | Nasal drops 0.05 % | 1 ML | 3.74 |
18 | Nasal drops 0.1% | 1 ML | 4.57 | |
19 | Bisacodyl | Suppository 5mg | 1 Suppository | 8.90 |
20 | Levetiracetam | Injection 100mg/mL | 1 ML | 20.53 |
21 | Ondansetron | Injection 2mg/mL | 1 ML | 5.32 |
22 | Paracetamol | Suppository 80mg | 1 Suppository | 5.94 |
23 | Paracetamol | Suppository 170mg | 1 Suppository | 7.09 |
24 | Methylergometrine | Injection 0.2mg/mL | 1 ML | 13.33 |
25 | Cytosine arabinoside | Injection 100mg/vial | 1 Vial | 124.49 |
26 | Cytosine arabinoside | Injection 500mg/vial | 1 Vial | 478.32 |
27 | Ketamine | Injection 50mg/mL | 1 ML | 10.81 |
28 | Vincristine | Injection 1mg/mL | 1 ML | 51.30 |
29 | Tramadol | Injection 50mg/mL (upto 2ml pack) | 1 ML | 10.51 |
30 | Oxytocin | Injection 5 IU/mL | 1 ML | 15.91 |
31 | Azithromycin | Oral liquid 200 mg/5 mL (p) | 1 ML | 3.04 |
32 | Oral liquid 5mg/5mL(p) | 1 ML | 0.59 | |
33 | Amoxicillin (A) +Clavulanic acid (B) | Oral liquid 200 mg (A) + 28.5mg(B)/5 mL(p) | 1 ML | 1.80 |
34 | Cefixime | Oral liquid 50 mg/5 mL (p) | 1 ML | 1.45 |
35 | Cefixime | Oral liquid 100mg/5mL(p) | 1 ML | 2.13 |
36 | Rituximab | Injection 10mg/mL | 1 ML | 679.41 |
37 | Sodium bicarbonate | Injection (as per IP) - 8.4% | 1 ML | 1.20 |
38 | Primaquine | Tablet 15mg | 1 Tablet | 4.58 |
39 | Ritonavir | Tablet 100mg | 1 Tablet | 26.05 |
40 | Carbamazepine | Tablet 100mg | 1 Tablet | 0.95 |
41 | Ibuprofen | Oral liquid 100mg/5mL(p) | 1 ML | 0.20 |
42 | Zidovudine (A) +Lamivudine (B) +Nevirapine(C) | Tablet 300mg(A)+150mg(B)+200mg (c) | 1 Tablet | 18.85 |
43 | Spironolactone | Tablet 25mg | 1 Tablet | 1.95 |
Sl. No. | Name of the Scheduled Formulation | Dosage form and strength | Unit | Ceiling Price (Rs.) |
44 | Furosemide | Tablet 40mg | 1 Tablet | 0.81 |
45 | Verapamil | Tablet 80 mg | 1 Tablet | 1.42 |
46 | Verapamil | Tablet 40mg | 1 Tablet | 0.77 |
47 | Natamycin | Drops 5% | 1 ML | 20.85 |
48 | Homatropine | Drops 2% | 1 ML | 5.71 |
49 | Carboxymethyl cellulose | Drops 0.5% | 1 ML | 10.97 |
50 | Carboxymethyl cellulose | Drops 1% | 1 ML | 14.79 |
51 | Salbutamol | Inhalation (MDI/DPI*) 100mcg/dose | 1 MDI | 0.44 |
52 | Salbutamol | Respirator Solution (Solution for Nebulizer 5mg/mL) | 1 ML | 0.61 |
53 | Pyridoxine | Tablet 100 mg | 1 Tablet | 5.33 |
(a) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.
(b) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above-said table.
(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of the such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
(g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
(i) Consequent to the issue of the ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above-said date of notification, stand(s) superseded.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd